Surrey Heartlands

Joint Formulary & PAD

Tacrolimus - Transplant immunosuppression

You are here : Home > Formulary Search > Tacrolimus - Transplant immunosuppression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
  • Modified release capsules
  • Modified release tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :
Important

For EXISTING patients: GPs may continue to prescribe for existing post-transplant patients only. NHS England are looking to repatriate these patients in the future. GPs must not accept any new requests to prescribe for new patients.

 

Status 2

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :
Important

For NEW patients: RED drug for post-transplant. Funded by NHS England. GPs should not accept any requests to prescribe post-transplant.

Documentation

Shared Care
Tacrolimus for transplantation -Blue Information Sheet - Jan 2021.

PAD Profile

ChemicalSubstance :
Tacrolimus
Indication :
Transplant immunosuppression
Group Name :
Keywords :
solid organ transplant rejection
Brand Names Include :
Prograf, Adoport, Modigraf, Vivadex, Advagraf, Envarsus, Capexion, Tacni, Dailiport
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Tacrolimus is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Transplant immunosuppression.

Committee Recommendations (2)

06 Jan 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

FOR EXISTING PATIENTS only:
A BLUE information sheet has been developed to facilitate the accessibility and safe prescribing across the secondary/primary care interface for patients already being prescribed branded tacrolimus by their GP.

Tacrolimus should be prescribed BY BRAND to ensure consistency due to narrow therapeutic index. Switching of brands/ formulations poses a risk of toxicity or potential graft rejection.

NHS England are looking to repatriate these patients in the future. GPs must not accept requests to prescribe for new patients.

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

FOR NEW PATIENTS: The prescribing of tacrolimus is considered a RED drug, post-transplant only and is funded via NHS England for this indication. GPs should not accept any new request to start prescribing tacrolimus post-transplant. RED drugs are for specialist use in secondary / tertiary care – prescribing is to be initiated and continued by the specialist. GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.